Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions.

Abstract

BACKGROUND Regarding the assessment of brain metastatic lesions, [18F]FDG PET/CT encounters challenges due to heightened physiological uptake in normal brain tissue, resulting in poor tumor-to-background ratios (TBR). Detecting brain metastases accurately has long been a challenge with standard imaging methods. The elevated physiological uptake of [18F]FDG in normal brain parenchyma limits its ability to distinguish metastatic lesions owing to poor tumor-to-background contrast. On the other hand, radiolabeled fibroblast activation protein inhibitors (FAPI) have emerged as a newer imaging tracer, showing promise. This study aimed to collect available literature to assess FAPI's ability to detect brain metastases across various cancer types. METHODS We reviewed studies published up to April 2025, utilizing different databases, including Google Scholar, PubMed, and Scopus, primarily examining the performance of FAPI based on standardized uptake values (SUVs) and TBRs. Studies focusing on the diagnostic performance of FAPI-based PET for brain metastasis were included. The primary endpoint was the detection rate of FAPI-based tracers. RESULTS In 24 studies involving over 115 patients and more than 291 lesions, FAPI-based imaging detected of 87.9% lesions (95% CI: 76.1-94.3%, p < 0.001) compared to [18F]FDG by the detection rate of 46.3% (95% CI: 30.6-62.8%, p = 0.667). The comparison of detection rates of these modalities showed an OR of 10.78 (95% CI: 5.15-22.55, p < 0.001). FAPI radiotracers exhibited higher TBR compared to [18F]FDG PET/CT (SMD: 1.51, 95% CI: 0.86-2.16, p < 0.001). CONCLUSION In conclusion, FAPI-based tracers seem to surpass [18F]FDG PET in identifying brain metastases. FAPI imaging can potentially serve as a diagnostic tool that offers benefits over traditional methods. Further research is needed to verify its clinical effectiveness.